|Ticker||Status||Jurisdiction||Filing Date||CP Start||CP End||CP Loss||Deadline|
|Ticker||Case Name||Status||CP Start||CP End||Deadline||Settlement Amt|
|Ticker||Name||Date||Analyst Firm||Up/Down||Target ($)||Rating Change||Rating Current|
Salarius Pharmaceuticals (NASDAQ:SLRX) reported its Q2 earnings results on Friday, August 5, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
Salarius Pharmaceuticals beat estimated earnings by 10.0%, reporting an EPS of $-0.09 versus an estimate of $-0.1.
Revenue was down $571 thousand from the same period last year.
Last quarter the company missed on EPS by $0.04 which was followed by a 15.36% drop in the share price the next day.
To track all earnings releases for Salarius Pharmaceuticals visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: SLRX